RNA sequencing for AML patients
We systematically evaluated osimertinib's usage for treating AML patients from the subgroup with high level of CD34 and warrant clinical investigation in the treatment of refractory/resistant AML. Overall design: Examination of osimertinib sensitivity for AML patients with different expression levels of CD34.